医学
达巴万星
耐甲氧西林金黄色葡萄球菌
抗生素
利奈唑啉
随机对照试验
重症监护医学
临床试验
金黄色葡萄球菌
内科学
万古霉素
微生物学
遗传学
生物
细菌
作者
Matteo Bassetti,Laura Magnasco,Filippo Del Puente,Daniele Roberto Giacobbe
出处
期刊:Current Opinion in Infectious Diseases
[Ovid Technologies (Wolters Kluwer)]
日期:2020-04-01
卷期号:33 (2): 110-120
被引量:11
标识
DOI:10.1097/qco.0000000000000631
摘要
Purpose of review To summarize the available efficacy and safety data of novel agents for treating acute bacterial skin and skin-structure infections (ABSSSI), focusing on those active against methicillin-resistant Staphylococcus aureus (MRSA). Recent findings There are now several agents active against MRSA that are approved for the treatment of ABSSSI, including tedizolid, ceftaroline, dalbavancin, telavancin, oritavancin, delafloxacin, and omadacycline. In addition, iclaprim has completed phase-3 randomized clinical trials (RCTs). Summary Considering the similar efficacy that arose from direct comparisons in phase-3 RCTs, in order to adopt the best approach for treating ABSSSI on patient-tailored basis, the different safety profiles and formulations of the different available agents should be balanced by taking into account the specific features of each treated patient in terms of baseline comorbidities, related risk of toxicity, need for hospitalization, possibility of early discharge, and expected adherence to outpatient oral therapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI